Stock Insights: Kirby, Penn National,, GlaxoSmithKline, BioMarin May 18th

Kirby Corporation (NYSE:KEX): Wunderlich lowered its price target after Kirby said it expects to hit the low end of guidance due to unforeseen maintenance expenses in the Kirby Offshore Marine segment. However, the firm remains positive on the name with a Buy rating.

Penn National Gaming Inc. (NASDAQ:PENN): Morgan Stanley believes Penn National’s new projects are underestimated and that estimates will begin to move higher over the summer. Shares are Overweight rated with a $53 price target. (NYSE:CRM): Morgan Stanley raised estimates and still sees further room for upside. Shares are Overweight rated.

GlaxoSmithKline plc (NYSE:GSK): Citigroup believes GlaxoSmithKline’s (NYSE:GSK) BRAF/MEK combo will set the new standard of care for BRAF-mutant advanced melanoma, creating imminent competition to Roche’s (RHHBY) Zelboraf. The firm believes the new melanoma drugs highlight major upside for GlaxoSmithKline, and downside for Roche.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): BioMarin price target raised to $44 from $40 at Leerink

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.